课题基金 / 基金详情

SCH56592 IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE/PROTEASE INHIBITORS IN HIV

SCH56592 IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE/PROTEASE INHIBITORS IN HIV
SCH56592 与齐多夫定/拉米夫定/蛋白酶抑制剂联合治疗 HIV
批准号：
6115485
负责人：
FRANCESCA T. AWEEKA
金额：
$3.1万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6115485
关键词：
AIDS therapy antiAIDS agent antifungal agents clinical research combination chemotherapy drug interactions human subject human therapy evaluation indinavir lamivudine pharmacokinetics protease inhibitor ritonavir triazoles zidovudine

项目摘要

项目成果

FRANCESCA T. AWEEKA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study is designed to evaluate a potential pharmacokinetic (PK) interaction between indinavir (or ritonavir), zidovudine, lamivudine and an investigational traizole antifungal agent, SCH 56592. This new drug shares a cytochrome p450 metabolic pathway with the protease inhibitors and may interact with zidovudine as does fluconazole (a similar drug) . This study will involve both inpatient and outpatient visits by the subjects. The GCRC staff will aid in patient care and blood drawing. The total duration of the study is 20 days with 3 inpatient days. During the inpatient stays the subjects will receive oral study drugs and PK sampling.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimizing ACT use for African children in the setting of HIV and malnutrition
Pharmacodynamics of Antimalarial Chemoprevention
Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa
Pharmacodynamics of Antimalarial Chemoprevention
海外基金